



The ACME Laboratories Ltd.

MANUFACTURERS OF ETHICAL DRUGS & MEDICINES

ISO 9001: 2015 CERTIFIED COMPANY

Office Copy

Office Copy

Ref. No. ACME /CA/CS/2021/0087

10 August 2021

The Chairman

Bangladesh Securities and Exchange Commission
Securities Commission Bhaban
E-C/6, Agargaon,
Sher-e-Bangla Nagar Administrative Area,
Dhaka-1207.

Subject: Audited Status Report on utilization of Initial Public Offering Proceeds for the Month ended 31 July 2021 of The ACME Laboratories Ltd.

Dear Sir,

In compliance with the clause 3 & 4 of Part-C of the Letter of Consent vide no. BSEC/CI/BB-03/2014/143; dated: 15 March 2016 accorded by your esteemed organization, we are pleased to enclose herewith the Audited Status Report (as per revised format) on utilization of Initial Public Offering Proceeds for the Month ended 31 July 2021 of The ACME Laboratories Ltd. duly authenticated by the Board of Directors in its 132nd Meeting held on 10 August 2021 for your kind perusal and record please.

Thanking you and assuring of our best attention for all the time to come.


Mizanur Rahman Sinha
Managing Director

Enclosure: As stated above

Copy to: 01. The Managing Director, Dhaka Stock Exchange Limited
02. The Managing Director, Chittagong Stock Exchange Limited
03. The Chief Executive Officer, ICB Capital Management Limited

Corporate Office:

Court de la ACME

1/4 Kallayanpur, Mirpur Road

Dhaka-1207, Bangladesh.

Phone : +88-02-9004194-6

Fax : +88-02-9016872

E-mail : headoffice@acmeglobal.com



Plant:

Dhamrai, Dhaka, Bangladesh.

Phone : +88-02-7730881-2

+88-02-7730816-7, 7730142

Fax : +88-02-7730141

E-mail : plant@acmeglobal.com

Auditors' Report

Name of Client

The ACME Laboratories Ltd.
Utilization of IPO Proceeds
for the month ended 31 July 2021



Registered Office: AHSANDELL, 2/A, Mymensingh Road (2nd Floor), Shahbag, Dhaka-1000, Bangladesh.
Tel: +08802-966-0944, +8802-966-5095, Cell: +8801711-106302, +8801534-130750.
E-mail: pinaki_co@yahoo.com website: www.pinaki.com.bd

AUDITORS' REPORT

on

Utilization of IPO Proceeds

We have audited the annexed Statement of Initial Public Offering (IPO) Proceeds Utilization of The ACME Laboratories Ltd. for the month ended 31 July 2021.

Management's Responsibility for the IPO proceeds Utilization

Management is responsible for the preparation and fair presentation of these IPO proceeds utilization statement in accordance with Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

Auditor's Responsibility

Our responsibility is to express an independent opinion on these Initial Public Offering (IPO) proceeds utilization statement based on our audit. We conducted our audit in accordance with International Standards on Auditing (ISA), Bangladesh Securities and Exchange Commission Rules 1987, Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 and other applicable laws and regulations.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our Opinion, the Statement of Initial Public Offering (IPO) Proceeds Utilization, Prepared in accordance with Bangladesh Securities and Exchange Commission Rules 1987 and Condition laid down in clause 3 & 4 of PART-C of consent letter # BSEC/CI/BB-03/2014/143, Dated March 15, 2016 gives a true and fair view of the statement for the month ended 31 July 2021 and comply with the resolution of 42nd and 44th AGM of the company.

As per TOR, We draw attention to the following matter:

1. The Company has started commercial operation of Steroid and Hormone project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42nd AGM. Total project cost of BDT 1,660,591,186 is generated from the IPO fund.

2. The Company has started commercial operation of Penicillin project in the month of June 2019, which has been completed within the time limit approved by the shareholders in its 42nd AGM. Total project cost of BDT 400,000,000 is generated from the IPO fund.
3. The Company has also utilized accumulative amount of Tk. 501,772,232 up to 31 July 2021 in respect of API Project. During the month of July 2021, an amount of Tk. 38,088,147 has been utilized out of IPO fund in respect of Active Pharmaceuticals Ingredients (API) Project.

We also state that:

- a) IPO proceeds of Steroid and Hormone Project as well as Penicillin Project have been utilized for the purposes as specified in the resolution of 42nd AGM of the company;
- b) IPO proceeds have been utilized in line with the conditions of the BSEC's consent letter for the IPO;
- c) API project, for which IPO fund was raised, will be completed within the time frame as specified in the resolution of 42nd AGM of the company.
- d) Utilization of IPO proceeds is accurate for the purpose of the company as mentioned in the resolution of 42nd and 44th AGM of the company.
- e) Audit statement has been made on verification of all necessary documents/papers/vouchers in support of utilization of IPO proceeds making reconciliation with bank statements.

Dhaka

Date: 11 August 2021

Pinaki Das
Pinaki Das, FCA
Senior Partner
ICAB Enrol. No: 151
Pinaki & Company
Chartered Accountants

Name of the Company: The ACME Laboratories Ltd.
Amount (BDT) of capital raised through IPO: BDT 4,095,015,601 (Received amount BDT 4,095,015,601 less of foreign currency conversion loss)
Date of Issue of Subscription: 21 April 2016
Proceeds Receiving Date: 11 April 2016 to 21 April 2016
Last Date of Full Utilization of IPO Fund as per 40th AGM/42nd AGM: As stated in time line column

[Amount in BDT]													
S.L	Purpose mentioned in the 40th AGM/42nd AGM	Time Line		Cost Breakdown	Amount as per 40th AGM	Amount as per 42nd AGM	Amount as per 44th AGM	Status of Utilization			Remarks		
		As per 40th AGM	As per 42nd AGM					During the Month	Total Utilized Amount	Utilized %		Total on utilized amount	On utilized %
1	Steroid and Hormone Project	Within 2 years of receiving IPO fund, i.e. 2018	Civil Construction	375,800,000	334,934,878	334,934,878	334,934,878	-	334,934,878	100.00%	-	0.00%	
Machinery & Equipment			508,600,000	933,900,000	933,900,000	933,900,000	-	933,900,000	100.00%	-	0.00%		
Utility			319,600,000	353,700,000	353,700,000	353,700,000	-	353,700,000	100.00%	-	0.00%		
Warehouse			39,500,000	21,986,000	21,986,000	21,986,000	-	21,986,000	100.00%	-	0.00%		
Vehicle			5,000,000	5,000,000	5,000,000	5,000,000	-	5,000,000	100.00%	-	0.00%		
			Consultancy fee	26,300,000	1,200,000	1,200,000	1,200,000	-	1,200,000	100.00%	-	0.00%	
			Contingencies	13,200,000	9,870,308	9,870,308	9,870,308	-	9,870,308	100.00%	-	0.00%	
			Sub Total	1,358,000,000	1,660,591,186	1,660,591,186	1,660,591,186	-	1,660,591,186	100.00%	-	0.00%	
2	Penicillin Project	Within the month of March 2018	Civil Construction	116,000,000	142,922,303	142,922,303	142,922,303	-	142,922,303	100.00%	-	0.00%	
Machinery & Equipment			132,299,520	79,768,602	79,768,602	79,768,602	-	79,768,602	100.00%	-	0.00%		
Utility			117,154,000	146,345,797	146,345,797	146,345,797	-	146,345,797	100.00%	-	0.00%		
Warehouse			20,592,700	21,641,545	21,641,545	21,641,545	-	21,641,545	100.00%	-	0.00%		
Vehicle			3,000,000	2,901,503	2,901,503	2,901,503	-	2,901,503	100.00%	-	0.00%		
			Consultancy fee	5,963,780	1,420,250	1,420,250	1,420,250	-	1,420,250	100.00%	-	0.00%	
			Contingencies	5,000,000	5,000,000	5,000,000	5,000,000	-	5,000,000	100.00%	-	0.00%	
			Sub Total	400,000,000	400,000,000	400,000,000	400,000,000	-	400,000,000	100.00%	-	0.00%	
3	Active Pharmaceutical Ingredients (API)	Within 2-3 years after getting permission from the Ministry of Industries	Civil Construction	347,860,000	355,637,304	355,637,304	355,637,304	-	355,637,304	100.00%	-	0.00%	
Machinery & Equipment			493,000,000	250,495,241	250,495,241	250,495,241	-	250,495,241	100.00%	-	0.00%		
Utility			409,400,000	-	-	-	-	-	-	-	0.00%	-	0.00%
Warehouse			38,500,000	-	-	-	-	-	-	-	0.00%	-	0.00%
Vehicle			3,000,000	-	-	-	-	-	-	-	0.00%	-	0.00%
			Consultancy fee	23,635,200	-	-	-	-	-	0.00%	-	0.00%	
			Contingencies	12,917,600	-	-	-	-	-	0.00%	-	0.00%	
			Initial Working Capital	26,915,492	-	-	-	-	-	0.00%	-	0.00%	
			Sub Total	1,355,228,292	606,132,545	606,132,545	606,132,545	38,088,147	501,772,232	82.78%	104,360,313	17.22%	
4	Repayment of Bank Borrowing at 40th AGM	N/A	N/A		1,360,000,000	1,360,000,000	1,360,000,000	-	1,360,000,000	100.00%	-	0.00%	
5	IPO Expenses	N/A	N/A		68,291,870	68,291,870	68,291,870	-	68,291,870	100.00%	-	0.00%	
	Total				4,541,520,162	4,095,015,601	4,095,015,601	38,088,147	3,990,655,288	97.45%	104,360,313	2.55%	

Interest on IPO Proceeds in BDT (from FDR & SMD)
Un Utilized IPO Proceeds with interest income in BDT

On Behalf of Inland

Jahanara Kogin Saha
(Jahanara Mizan Saha)
Deputy Managing Director

Nagim Afzal Saha
(Nagim Afzal Saha)
Managing Director

Nagim Afzal Saha
(Nagim Afzal Saha)
Chairman

Pinaki & Company
Chartered Accountants